Meng Y, Zhang S, Aout M, Babcock A, et al. Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ 2025;28:1779-1797.
PMID: 41039930